4 Results for "

Trilaciclib

" in MedChemExpress (MCE) Product Catalog:
Products (4)

4 Results for "Trilaciclib" in MCE Product Catalog:

1
1 Cited Publications
Cat. No.: HY-101467
CAS No.: 1374743-00-6
Purity:  99.32%
Synonyms: G1T28
Target:  

CDK

Research Areas:  

Cancer

Trilaciclib (G1T28) is an orally active CDK4/6 inhibitor with IC50 values of 1 nM and 4 nM for CDK4 and CDK6, respectively. . Trilaciclib can effectively inhibit tumor cell proliferation and reduce the hematological toxicity caused by chemotherapy. Trilaciclib attenuates apoptosis and myelosuppression induced by 5FU (HY-90006) chemotherapy .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-101467A
CAS No.: 1977495-97-8
Purity:  99.69%
Synonyms: G1T28 hydrochloride
Target:  

CDK

Research Areas:  

Cancer

Trilaciclib (G1T28) hydrochloride is an orally active CDK4/6 inhibitor with IC50 values of 1 nM and 4 nM for CDK4 and CDK6, respectively. Trilaciclib hydrochloride can effectively inhibit tumor cell proliferation and reduce the hematological toxicity caused by chemotherapy. Trilaciclib hydrochloride attenuates apoptosis and myelosuppression induced by 5FU (HY-90006) chemotherapy .
loading...
    loading...
Cat. No.: HY-101467AR
CAS No.: 1977495-97-8
Synonyms: G1T28 hydrochloride (Standard)
Target:  

Reference Standards CDK

Research Areas:  

Cancer

Trilaciclib (hydrochloride) (Standard) is the analytical standard of Trilaciclib (hydrochloride). This product is intended for research and analytical applications. Trilaciclib hydrochloride (G1T28 hydrochloride) is a CDK4/6 inhibitor with IC50s of 1 nM and 4 nM for CDK4 and CDK6, respectively .
loading...
    loading...
Cat. No.: HY-101467R
CAS No.: 1374743-00-6
Synonyms: G1T28 (Standard)
Target:  

CDK Reference Standards

Research Areas:  

Cancer

Trilaciclib (Standard) is the analytical standard of Trilaciclib (HY-101467). This product is intended for research and analytical applications. Trilaciclib (G1T28) is an orally active CDK4/6 inhibitor with IC50 values of 1 nM and 4 nM for CDK4 and CDK6, respectively. . Trilaciclib can effectively inhibit tumor cell proliferation and reduce the hematological toxicity caused by chemotherapy. Trilaciclib attenuates apoptosis and myelosuppression induced by 5FU (HY-90006) chemotherapy .
loading...
    loading...